The effect of isotretinoin in the treatment of acne

Evaluation the effect of isotretinoin on androgen hormone level in women with acne vulgaris

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017052725407N2

Enrollment

Registered

2017-06-07

Start date

2014-02-17

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne. Acne Vulgaris

Interventions

Orally tablet of 20 mg isotretinoine (Roaccutane)daily for a period of three months.

Treatment - Drugs

Orally tablet of 20 mg isotretinoine (Roaccutane)daily for a period of three months

Eligibility

Sex/Gender

Female

Age

18 Years to 30 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 18-30 years old women with moderate to severe acne vulgaris. Exclusion criteria: pregnancy; hypersensitivity to parabens; poly cystic ovarian disease; recent history of mood or depressive disorders; thyroid disease; pituitary disease and use of Finasteride; retinoids or hormonal contraception within three months of enrollment.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Dihydrotestosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;17-hydroxyprogestrone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Testosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Dehydroepiandrosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Free testosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Luteinizing hormone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Follicle stimulating hormone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Prolactin. Timepoint: Before and after the intervention. Method of measurement: ng/ml.	—

Measure

Time frame

Dihydrotestosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;17-hydroxyprogestrone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Testosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Dehydroepiandrosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Free testosterone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Luteinizing hormone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Follicle stimulating hormone. Timepoint: Before and after the intervention. Method of measurement: ng/ml.;Prolactin. Timepoint: Before and after the intervention. Method of measurement: ng/ml.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Amir Feily

Jahrom University of Medical Sciences

edu@jums.ac.ir+98 71 5444 0821

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026